Table 2 Comparison of the basic indicators between the two groups after treatment
From: The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
Groups | N | BMI (x ± s, kg/m2) | HbA1c (x ± s, %) | sCr (x ± s, μmol/L) | UA (x ± s, μmol/L) | uMA/uCr (μg/mg) | |
|---|---|---|---|---|---|---|---|
Control group | 60 | Before treatment | 25.94 ± 2.51 | 9.36 ± 1.44 | 140.21 ± 34.84 | 366.10 ± 68.54 | 251.52 ± 57.29 |
After treatment | 25.3 ± 2.21 | 7.37 ± 0.91 | 121.63 ± 25.40 | 345.54 ± 61.22 | 196.57 ± 45.36 | ||
Experimental group | 60 | Before treatment | 26.13 ± 2.35 | 9.31 ± 1.72* | 143.08 ± 36.33* | 371.40 ± 69.59* | 256.55 ± 58.10* |
After treatment | 24.08 ± 2.33*# | 6.73 ± 0.56*# | 104.10 ± 24.68*# | 321.57 ± 60.91*# | 173.47 ± 46.16*# |